These data support a predominant role for GPx2 KD in regulating the tumor response; however, they do not rule out that mild increases in PRDX2 or PRDX5 do not contribute to tumor aggressiveness, especially since these antioxidants were shown to be associated with worse patient prognosis (32). Here, PRDX2 is linked to neoplasm.